With only one company allowed to give the test, no wonder prices are sky high.
When Angelina Jolie announced in The New York Times that she had undergone a double mastectomy because she carries a gene, BRCA1, that increases her risk of developing breast and ovarian cancers, it brought many issues to light. She talked about her decision, the procedure and what it meant for her family.
Jolie also noted that more women ought to have access to gene testing, regardless of their income, and she acknowledged, "The cost of testing for BRCA1 and BRCA2, at more than $3,000 in the United States, remains an obstacle for many women." Jolie did not mention, however, why the price of this important test is so prohibitive.
Myriad Genetics owns the patent for BRCA1 and BRCA2 genes-not a patent for the test, but a patent for the actual human genes . That means Myriad can prevent anyone from testing, studying or even looking at these genes, and it also holds exclusive rights to mutations along these genes. "OtherRead More »from What Angelina Jolie's Op-Ed Didn't Tell You